Prolacta Bioscience Revenue and Competitors

Prolacta Bioscience, headquartered in Monrovia, Calif., provides pharmaceutical grade specialty formulations of human milk for use in the nutrition of low birth weight (LBW) and very low birth weight (VLBW) babies. Prolacta sells its products directly to the neonatal intensive care units (NICU) of hospitals, specializing on the nutritional needs of underweight and critically ill babies, focused on the first 30 days of life. Prolacta Bioscience has developed improved methods for testing, formulating and processing of human milk. Prolacta's dedication to quality assurance in milk testing ensures that hospitals and physicians can trust the Prolacta's human milk formulations provided to premature babies meet the highest quality and safety standards. Prolacta's large-capacity human milk processing capabilities ensures a steady supply of high-quality human milk formulations targeted specifically to meet the requirements of very low birthweight premature infants. Prolacta is committed to ensuring that all babies receive the benefits of human milk. To achieve this, Prolacta is helping communities establish milk banks to address the critical shortage of human milk for sick babies. PROLACTA IS ALSO COMMITTED TO SUPPORTING RESEARCH IN THE AREAS OF HUMAN MILK AND PREMATURE INFANT NUTRITION IN ORDER TO ASSIST HEALTH CARE PROFESSIONALS IN PROVIDING THE BEST POSSIBLE CARE FOR THESE VULNERABLE BABIES.